SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Editorial board of the cancer statistics in Japan. Cancer statistics in Japan 2005. Foundation for promotion of cancer research (FPCR).
  • 2
    Detterbeck FC. Diagnosis and treatment of lung cancer. In: An Evidence-Based Guide for the Practicing Physician. Philadelphia: WB Saunders; 2000.
  • 3
    Buizebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer. 1992; 70: 11021110.
  • 4
    Livingston RB. Combined modality therapy of lung cancer. Clin Cancer Res. 1997; 3: 26382647.
  • 5
    Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996; 88: 12101215.
  • 6
    Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 1996; 125: 723729.
  • 7
    Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer: a meta-analysis. Cancer. 1995; 76: 593501.
  • 8
    Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311: 899809.
  • 9
    Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999; 17: 26922699.
  • 10
    Curran W, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 [Abstract]. Proc Am Soc Clin Oncol. 2003; 22: 621.
  • 11
    Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologic Thoracique-Groupe Francais de Pneumo-Cancerologic NPC 95-01 Study. J Clin Oncol. 2005; 23: 59105917.
  • 12
    Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48: 17221726.
  • 13
    Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxyl lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem. 1989; 32: 715720.
  • 14
    Masuda N, Kudoh S, Fukuoka M. Irinotecan (CPT-11): pharmacology and clinical applications. Crit Rev Oncol/Hematol. 1996; 24: 326.
  • 15
    Fukuda M, Nishio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in a human small cell lung cancer cells. Cancer Res. 1996; 56: 789793.
  • 16
    Kanzawa F, Sugimoto Y, Minato K, et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 1990; 50: 59195924.
  • 17
    Masuda N, Fukuoka M, Fujita A, et al. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer. 1998; 78: 251256.
  • 18
    Negoro S, Masuda N, Takada Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003; 88: 335341.
  • 19
    Tamura K, Takada M, Kawase I, et al. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res. 1997; 88: 218223.
  • 20
    Yokoyama A, Kurita Y, Saijo N, et al. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy forunresectable stage III non-small-cell lung cancer. Br J Cancer. 1998; 78: 257262.
  • 21
    Oka M, Fukuda M, Fukuda M, et al. Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer. Eur J Cancer. 2001; 37: 13591365.
  • 22
    Cancer Therapy Evaluation Program. Common toxicity criteria, version 2. Bethesda, MD: National Cancer Institute; 1998.
  • 23
    World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO; 1979.
  • 24
    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 25
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 26
    Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007; 18: 317323.
  • 27
    DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1999; 17: 27102720.
  • 28
    Takeda K, Negoro S, Kudoh S, et al. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer. 1999; 79: 14621467.
  • 29
    Somer R, Langer C, Movsas B, et al. Phase I study of irinotecan (CPT-11), cisplatin (cDDP) and radical thoracic radiation (TRT) in the treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol. 2002; 21: 332a. Abstract 1287.
  • 30
    Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the cancer and leukemia group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 1999; 17: 411.
  • 31
    Oka M, Fukuda M, Kuba M, et al. Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer. Eur J Cancer. 2002; 38: 19982004.
  • 32
    Jeong HC, Lee SY, Lee SY, et al. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung Cancer. 2006; 53: 361366.
  • 33
    Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005; 23: 58835891.
  • 34
    Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003; 21: 20042010.
  • 35
    Jeremic B, Milicic B, Acimovic L, et al. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study. J Clin Oncol. 2005; 23: 11441151.